Arch Biopartners and University of Cincinnati Enter Option Agreement for Treatment of Bacterial Respiratory Infections

Arch Biopartners Inc. (CNSX:ACH,OTCBB:FOIFF) and the University of Cincinnati have entered into a one year option agreement for the exclusive licensing of the commercial rights to a U.S. Patent for treating bacterial respiratory infections using acidified nitrite.

As quoted in the press release:

During the option period, Arch and Dr. Hassett’s team within the UC network will assess the potential and logistics of conducting a Phase II clinical trial to test the technology’s efficacy in treating bacterial respiratory infections that are resistant to antibiotics.

Click here to read the Arch Biopartners Inc. (CNSX:ACH,OTCBB:FOIFF) press release